Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Florida: - Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- Bay Pines VA Healthcare System — Bay Pines, Florida
- Jupiter Medical Center — Jupiter, Florida
- Mount Sinai Medical Center — Miami Beach, Florida
- Moffitt Cancer Center at SouthShore — Ruskin, Florida
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Florida: - Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Florida: - Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- Baptist MD Anderson Cancer Center — Jacksonville, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Florida: - Malcom Randall Veterans Administration Medical Center — Gainesville, Florida
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Florida: - Advanced Urology Institute, LLC — Largo, Florida
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Florida: - AdventHealth Orlando — Orlando, Florida
- Florida Cancer Specialists — Sarasota, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Florida: - Bay Pines VA Healthcare System — Bay Pines, Florida
- Florida Cancer Specialists & Research Institute — Fort Myers, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Florida: - Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0077) — Jacksonville, Florida
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Florida: - Florida Cancer Specialists - South ( Site 7003) — Fort Myers, Florida
- Bruce W. Carter Veterans Affairs Medical Center ( Site 0082) — Miami, Florida
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051) — Miami, Florida
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Florida: - Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Florida: - Research Site — Hialeah, Florida
- Research Site — Jacksonville, Florida
- Research Site — Tallahassee, Florida
- Research Site — Tampa, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Florida: - Cancer Specialists of North Florida — Jacksonville, Florida
- Woodlands Medical Specialists — Pensacola, Florida
Phase 3 Recruiting Industry
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…
Sponsor: BioNTech SE
NCT ID: NCT07365995
Sites in Florida: - Florida Cancer Specialists- Fort Myers — Fort Myers, Florida
- Florida Cancer Specialists- St. Petersburg — St. Petersburg, Florida
- Florida Cancer Specialists- West Palm Beach — West Palm Beach, Florida
Phase 3 Recruiting Industry
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prosta…
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT07052214
Sites in Florida: - Impression Imaging — Boca Raton, Florida
- University of Miami — Miami, Florida
Phase 3 Recruiting Industry
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamid…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT07723248
Sites in Florida: - SSAK Partners, LLC — Coral Springs, Florida
Phase 2, Phase 3 Recruiting Academic/Other
This study will enroll 60 patients previously enrolled to MCC#18523, "A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men with Prostate Cancer: (VANDAAM)" that…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT03495427
Sites in Florida: - H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Florida: - Jupiter Medical Center — Jupiter, Florida
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Florida: - Mayo Clinic Jacksonville — Jacksonville, Florida
- Moffitt Cancer Center - McKinley Drive — Tampa, Florida
Phase 2 Recruiting Industry
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…
Sponsor: Pfizer
NCT ID: NCT04606446
Sites in Florida: - Holy Cross Hospital — Fort Lauderdale, Florida
Phase 1, Phase 2 Recruiting Industry
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in Florida: - Florida Cancer Specialists — Sarasota, Florida
Phase 2 Recruiting Industry
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…
Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in Florida: - D&H Cancer Research Center, LLC — Margate, Florida
- BRCR Global — Plantation, Florida
Phase 2 Recruiting Industry
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurat…
Sponsor: Sun Pharmaceutical Industries Limited
NCT ID: NCT05422911
Sites in Florida: - James A. Haley Veterans Administration Hospital — Tampa, Florida
Phase 2 Recruiting Industry
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are ano…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07005154
Sites in Florida: - H. Lee Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Sponsor: AstraZeneca
NCT ID: NCT07590934
Sites in Florida: - Research Site — Miami, Florida
- Research Site — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Florida: - Sylvester Comprehensive Cancer Center - University of Miami Health System — Miami, Florida